EXJADE®


Dispersible tablets
scheduling status
S4
registration number
A40/27/0266; A40/27/0267; A40/27/0268
What EXJADE® contains
EXJADE 125 mg dispersible tablets contains 125 mg deferasirox. EXJADE 250 mg dispersible tablets contains 250 mg deferasirox. EXJADE 500 mg dispersible tablets contains 500 mg deferasirox.
other ingredients
Lactose monohydrate, crospovidone, microcrystalline cellulose, povidone (K30), sodium lauryl sulphate, silicon dioxide, magnesium stearate. Contains lactose monohydrate.
Therapeutic classification
Pharmacological classification: A27 Chelating agents (versenates) as heavy metal antidotes.
© 2026 SAHPRA. ALL RIGHTS RESERVED